glp-1 news november 6 2025 Ozempic Pitfalls and Natural Weight Balance | The American Chiropractor Stopping and restarting GLP-1s may

In summary, while GLP-1 RAs hold substantial promise as dual-action agents addressing both metabolic dysfunction and neuropsychiatric symptoms, their integration into psychiatric care demands rigorous clinical trials, biomarker-guided stratification, and mechanistic validation

38 Ertugliflozin EMA product information (2023)

Payers should track weight maintenance and adherence instead of prescription starts alone

Part D and Medicare Advantage plans may list these drugs on their formularies, but coverage usually requires prior authorization and documentation that they are being prescribed for diabetes, cardiovascular risk, or another FDAapproved indication, not simply to lose weight. Commercial coverage is all over the map: some employer and individual plans cover GLP1s for obesity with strict criteria (BMI thresholds, participation in a weightmanagement program, timelimited authorizations), while others have moved to exclude them because of cost

Assessment of Gastric Content Using Gastric Ultrasound in Patients on Glucagon-Like Peptide-1 Receptor Agonists Before Anesthesia

10, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only